Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Multiple myeloma (MM) is a cancer of plasma cells that has been extensively studied in
recent years, with researchers increasingly focusing on the role of microRNAs (miRNAs) in …

Multiple myeloma (MM) is a tumor of transformed plasma cells. It's the second most common
hematologic cancer after non-Hodgkin lymphoma. MM is a complex disease with many …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor
(CAR) T-cell therapies represent a promising treatment strategy with high response rates in …

Multiple myeloma is the second-most common hematologic malignancy in adults worldwide.
Despite ongoing advancement in therapeutic modalities, it remains an incurable disease …

Background Chimeric antigen receptor-T (CAR-T) cell therapy has shown remarkable
efficacy in patients with relapsed/refractory multiple myeloma (R/R MM). However, a subset …

Background Pancreatic cancer, referred to as the “monarch of malignancies,” is a neoplastic
growth mostly arising from the epithelial cells of the pancreatic duct and acinar cells. This …

Recently, multiple chimeric antigen receptor T‐cell (CAR‐T)‐based therapies have been
approved for treating hematological malignancies, targeting CD19 and B‐cell maturation …

Andrographis paniculata is used as a functional food in Asia. Andrographolide (Andro), a
diterpene lactone isolated from Andrographis paniculata, has been reported to have potent …